GLI2 Regulates TGF-β1 in Human CD4+ T Cells: Implications in Cancer and HIV Pathogenesis

Elevated levels of the immunoregulatory cytokine TGF-β1 in cancer and HIV infection have been linked to the suppression of protective immune responses. The transcriptional regulation of TGF-β1 is complex and still not completely understood. We report here for the first time that the transcription factor GLI2 regulates the expression of TGF-β1 in human CD4+ T cells. In silico screening revealed five novel putative GLI binding sites in the human TGF-β1 promoter. At least two of these sites within the human TGF-β1 promoter are regulated by the GLI2 activator as knockdown of GLI2 in regulatory CD4+CD25hi T cells, high producers of TGF-β1, significantly decreased TGF-β1 transcription. Additionally, naïve CD4+ T cells, low producers of TGF-β1, increased their basal level of TGF-β1 mRNA following lentiviral infection with GLI2. The transcriptional regulation of TGF-β1 by GLI2 is a new extension to Sonic Hedgehog (SHH) and TGF-β1 cross-regulation and may provide insight into the detrimental elevation of TGF-β1 leading to pathogenesis in cancer and HIV infection.


Introduction
Transforming Growth Factor-b1 (TGF-b1) is a pleiotropic cytokine that regulates the immune response in many diseases including cancer and HIV infection and plays an important role in preventing pathogenesis [1][2][3][4][5]. It is produced by several cell types including CD4 + CD25 hi regulatory T cells, macrophages, as well as by fibroblasts. TGF-b1 decreases proliferation of T and B lymphocytes, effector functions of many cells of the immune system and induces peripheral regulatory T cells [6]. Although TGF-b1 is critical throughout mammalian development and to prevent aberrant activation of the host's immune system, elevated expression of TGF-b1 can dampen protective immune responses to tumors and infections.
Aberrant high production of TGF-b1 by malignant cells was shown to increase metastasis as well as to prevent a protective host immune response to tumors [7]. In chronic HIV infection, TGF-b1 is elevated in several compartments including lymphoid tissues, blood, and cerebrospinal fluid [8][9][10]. Increased levels of TGF-b1 can induce the development of induced (i)Treg observed in chronic HIV infection [11,12], and may contribute to dysfunction of the immune system during late-stage disease. The HIV-1 Tat protein induces TGF-b1 in human leukocytes [13][14][15], chondrocytes [16], and also in murine CD2 + T cells of a Tat-transgenic mouse model [17]. The mechanisms of tumor-induced and Tatmediated TGF-b1 induction are unknown. Cancer and AIDS are only two of the many diseases in which TGF-b1 plays a role in pathogenesis.
Expression of active TGF-b1 is tightly regulated at the transcriptional, translational, and post-translational levels. Although TGF-b1 expression has been a focus of intense investigation, we are still far from understanding this cytokine's complex regulation. In silico analysis of the TGF-b1 promoter region indicates several putative binding sites of known transcription factors. Some of these transcription factors, like Sp-1 and Zf9, have previously been found to mediate TGF-b1 transcription, but these factors alone are not sufficient to induce mRNA expression [18,19]. Therefore we investigated which other transcription factors induce TGF-b1 mRNA.
We found six putative binding sites (five previously unreported) for the human GLI transcription factors by in silico analysis of the human TGF-b1 promoter. The GLI2 transcription factor is one of the main downstream effectors of the Sonic Hedgehog (SHH) pathway, which was shown to play a role in the function of the adaptive immune system [20,21]. The SHH pathway modulates activation [22], proliferation [23,24], and cytokine regulation [25] in CD4 + T cells. Since several interactions between the TGF-b1 and SHH pathways exist (Table 1), we focused on regulation of TGF-b1 by SHH pathway family members, i.e. GLI proteins, in the immune system.
We provide evidence that at least two of the six putative GLIbinding sites are required for GLI2-mediated transcriptional regulation of the human TGF-b1 promoter. At least one of these two sites must be functional to observe TGF-b1 regulation by GLI2. Furthermore, by knocking down GLI2 in human CD4 + CD25 hi Treg, we show that GLI2 is necessary for TGF-b1 expression. The transcriptional regulation of TGF-b1 by GLI2 has not yet been described and increases our understanding of the complexities of TGF-b1 regulation.

Ethics Statement
The use of anonymous peripheral blood mononuclear cells to obtain T cells and the epithelial 293T cell line was reviewed by the UCLA Institutional Review Board (IRB), which concluded that this activity did not involve human subjects, and therefore did not require IRB review or certification.

In Silico Screening
Screening for putative GLI binding sites in the human TGF-b1 promoters was done by in silico analysis using the software program MatInspector (http://www.genomatix.de). A range of twenty kilobases surrounding the first human TGF-b1 promoter were used to screen for putative transcription factor binding sites. All six putative GLI binding sites within the first kilobase of TGF-b1 promoter #1 (five potential sites) or promoter #2 (one potential site) had a matrix similarity score equal to or greater than 0.8. Binding sites found within the first proximal promoter region are novel and are the focus of this study.

Luciferase & Promoter Studies
The human TGF-b1 promoter-luciferase reporter constructs, phTG5 and phTG1, were kindly provided by S.J. Kim [18]. The wild-type phTG5 construct was mutated at the putatitve GLI binding sites (site A, B, or A and B) using site-directed mutagenesis (SITE A: 59-CAGCCCCCCCATGCC-39 to 59-CAGCaa-CaaaATGC-39, SITE B: 59-GAGCCCGCCCACGCGA-39 to 59-GAGCaaGaaaACGCGA-39, mutated bases in lower case). The wild-type phTG1 construct was mutated at putative GLI binding Site E using site-directed mutagenesis (SITE E: 59-CCCAC-CACCCACGAA-39 to 59CCaAaaAaaaACGAA-39, mutated bases in lower case). The wild-type promoter, the mutated promoters, or a pGL3 empty-vector control were individually co-transfected with the constitutive activator vector pGLI2DN (kindly provided by E. Roessler [26]) or the control pcDNA3 with Lipofectamine 2000 using standard procedures into 293T cells, a human epithelial cell line containing Adeno and SV-40 viral DNA sequences, obtained from the American Type Culture Collection (ATCC). The pGLI2DN plasmid contains a constitutively active GLI2 gene due to an amino-terminal truncation. The amino terminal domain of the human GLI2 gene has a repressive function, and it's removal has been shown to increase transcription of downstream target genes such as GLI1 [26]. The 293T cell line was chosen because of its transfection efficiency and low levels of GLI1 expression, which is our readout for GLI2 activation. Luciferase expression was measured at 48 hours post-transfection.

Cell Isolation, Culture, & Stimulation
Naïve CD4 + T cells, expressing CD4, CD31, CD45RA, and CD62L, were purified and isolated from human peripheral blood mononuclear cells (PBMC) using negative selection. CD4 + CD25 hi regulatory T cells were enriched from human blood using RosetteSep and Robosep kits from Stem Cell Technologies. Primary cells were cultured in serum-free medium consisting of Iscove's Modified Dulbecco's Medium supplemented with delipidated BSA (Sigma-Aldrich) at 1100 mg/mL, human transferrin (Sigma-Aldrich) at 85.5 mg/mL, 2 mM glutamine, and penicillin/ streptomycin at 25 U/25 mg/mL. All stimulation conditions of primary T cells were done with aCD3/aCD28-coated M-450 beads from Invitrogen. Cell surface and intracellular immunophenotypes were validated by flow cytometry as described previously [27]. For detection of intracellular FoxP3, cells were first stained for cell surface markers, fixed and permeabilized with eBioscience recommended buffers following manufacturer instructions, then incubated with FITC or eFluor 450 conjugated monoclonal antibodies against FoxP3 (eBioscience, clone PCH101).

siRNA Knockdown
Knockdown of GLI2 in primary human regulatory T cells was done using ACCELL siRNA designed and validated by Thermo-Fisher/Dharmacon. A non-targeting siRNA was used as a negative control. A positive control siRNA for GAPDH was used to verify knockdown. Knockdown of GLI2 was done using a commercially available and validated siRNA from Dharmacon (A-006468-14 -Target sequence -5' GGUUUGAAUCUGAAUG-CUA 3'). A separate independent negative control using a scrambled GLI2 siRNA sequence (5'-AAGGUAUGCG-CUUAAUUU-3') was used to address off-target effects. GLI2 knockdown was verified by assessing GLI1 mRNA expression following stimulation. GLI1 has been previously shown to be transciptionally regulated by GLI2 and is the positive control for GLI2 knockdown.
Purified CD4 + CD25 hi FoxP3 + regulatory T cells were incubated with the siRNA and serum-free ACCELL medium (Dharmacon) for 72 hours prior to stimulation with aCD3/aCD28 coated beads. Twenty-four hours post-stimulation, cells were collected to measure TGF-b1 mRNA levels by RT-PCR. TGF-b1 levels were normalized to 18S rRNA and compared to unstimulated cells.

RT-PCR
Taqman Gene Expression primer/probe sets for TGF-b1, GLI1, 18S rRNA, and GAPDH from Applied Biosystems Inc. were used to measure transcripts levels in various conditions. The expression of TGF-b1, GLI1, and GAPDH were normalized to 18S rRNA levels and relative expression between conditions was calculated to assess upregulation/downregulation of transcription.

Lentiviral Infections
The GLI2DN transgene was placed into a third-generation HIV-1 vector at the UCLA Vector Core. The majority of the HIV viral coding sequence was removed and replaced by the transgene. The LTRs were modified to be "self-inactivating,'' and the transcription of the vector genome in the packaging cells was driven by a non-HIV promoter. Virus was made using 293T cells that were co-transfected with the vector plasmid and three other plasmids encoding A) the viral enzymes and structural proteins, except Env, B) Rev, which is involved in HIV RNA transport, and C) VSV glycoprotein, which is a pan-tropic envelope that allows virus entry into almost any cell type. Naïve CD4 + T cells were infected with 100 ng p24 per million cells in serum-free medium for 96 hours. RNA was isolated for determination of changes in gene expression using RT-PCR. A GFP-containing lentivirus was used as a negative control and also to measure infection efficiency.

Chromatin Immunoprecipitation (ChIP)
ChIP analysis was done to determine whether GLI2 binds to the TGF-b1 promoter. Regulatory CD4 + CD25 hi T cells were negatively isolated as described above. The cells were stimulated with aCD3/aCD28-coated beads overnight. The GLI2 Exacta-ChIP kit (R&D Systems) was used for chromatin immunoprecipitation. Cells were fixed, lysed, and sonicated prior to incubation with either aGLI2-coated or control aIgG-coated agarose beads. PCR was done following ChIP to assess GLI binding to the TGF-b1 promoter. Putative GLI2 binding site 'E' (Figure 1) was detected using designed primers (59-CTGGGGTCAGCTCTGA-CAGT-39 and 59-CAGTTGGCGAGAACAGTTGG-39; 290 bp fragment). The Bcl2 promoter region was detected as a positive GLI-binding control using primers from the ExactaChIP kit. A 238 bp region of the IL-10 promoter which contained no putative GLI2 binding site was measured as a negative control (59-TGATTTCCTGGGGAGAACAG-39 and 59-CCCACCCCCT-CATTTTTACT-39).

Co-Immunoprecipitation
Co-immunopreciptation was performed to assess the binding of human GLI2 to HIV-1 Tat. Dual transfections were done in 293T cells using three different sets of plasmids: (GLI2-6xMYC + HIV-1 Tat-FLAG), (GLI2-6xMYC + PCDNA3 control), (HIV-1 Tat-FLAG + PCDNA3 control). Forty-eight hours post-transfection, the cells were lysed and the released proteins were collected for co-IP (Pierce Co-IP Kit from Thermo Scientific). The agarose resin was coated with one of three antibodies: Sigma F1804 anti-FLAG M2 antibody (to bind Tat to bead), CST 71D10 anti-MYC antibody (to bind GLI2 to bead), or an isotype control antibody. Following co-IP, the elutions were run on an SDS-PAGE gel followed by Western Blotting.

Statistics
All analyses were conducted by the UCLA AIDS Institute Biostatistics Core or with GraphPad Prism 5 Software. Variables were expressed as means with standard error of the mean. ANOVA and two-tailed Wilcoxon Rank sum test, paired when appropriate, were used to analyze differences between populations. A p value lower or equal to 0.05 was considered significant.

Six Putative GLI Binding Sites Lie Within the Human TGF-b1 Promoters
Through in silico analysis using MatInspector (http://www. genomatix.de) we found six putative GLI binding sites within the two reported human TGF-b1 promoters, including a previously reported site within the second promoter [28] in addition to five sites which were previously unidentified. Both Genomatix software and UCSC genome (www.genome.ucsc.edu) programs indicate a high degree of sequence conservation surrounding the TGF-b1 promoter region in mammals which suggests the functional relevance of the human TGF-b1 promoters. The consensus binding sequence for the GLI transcription factors has been identified as 59-TGGGTGGTC-39 [29,30]. The six putative GLI binding sites reported in this study have a high-degree of matrix similarity 43 and are listed in Figure 1. The abundance of possible GLI binding sites within the first thousand base pairs of the transcription start site of the TGF-b1 promoter suggests that this proximal promoter region may be regulated by the GLI transcription factors.

GLI2 Activates the First Human TGF-b1 Promoter Through At Least Two of the Putative GLI-binding Sites
The putative GLI binding site in the second TGFb-1 promoter has been reported to be non-responsive to SHH stimulation by Eichenmuller et al. [28]. However, the five putative sites in the first promoter have not previously been reported to be regulated by GLI proteins. We used a reporter construct containing the first 500 base pairs of the human TGF-b1 promoter which was placed upstream of the firefly luciferase gene by Kim et al. (phTG5) [18]. This expression vector was co-transfected into 293T cells along with a constitutive GLI activator construct pGLI2DN [26] or a pcDNA3 plasmid control to assess GLI2-mediated regulation of the promoter of the human TGF-b1 gene.
Following co-transfection of GLI2DN and phTG5 into 293T cells, we observed an approximately 4-fold increase of luciferase There are two reported promoters in the human TGF-b1 gene. In silico analysis of the human TGF-b1 proximal promoter regions using the Genomatix software program revealed five previously unidentified putative GLI-binding sites (A through E) in a highly conserved region of the human genome. Site F in the second promoter has previously been identified and studied [28]. Sites A and B (which overlaps with C), all lie within the luciferase reporter construct phTG5 used in the promoter mutagenesis studies. Site E is present in the phTG1 construct. Approximate base pair positions of potential GLI binding sites are shown relative to the two reported transcription start sites for the human TGF-b1 gene. doi:10.1371/journal.pone.0040874.g001 expression over the controls (Figure 2). As the promoter region of phTG5 contains three of the six putative GLI binding sites (A, B, & C) we used site-directed mutagenesis to mutate these putative GLI binding sites individually or in combination (denoted phTG5A, phTG5B, and phTG5AB respectively). Although mutation of a single site only modestly reduced luciferase expression, mutation of both sites reduced reporter gene expression down to control levels. These findings indicate that GLI2 can activate transcription at the human TGF-b1 promoter and that binding to at least one of these sites is required for this to occur. Mutation at Site E, which lies further upstream of the transcription start site, was done to assess its role in GLI2-induced TGF-b1 expression. We used a luciferase reporter construct phTG1 containing 21362 to +11 bases near the transcription start site of the human TGF-b1 promoter [18]. Following mutation of the possible GLI-binding site, the luciferase expression was decreased approximately two-fold following cotransfection with the constitutive GLI2 activator. Further analysis will be needed to Activated GLI2 Can Enhance TGF-b1 Transcription in Naïve CD4 + T cells In order to investigate the effect of the GLI transcription factors in primary cells, we infected primary naïve CD4 + T cells with lentiviral vectors containing the constitutive activator GLI2DN or a GFP control. Expression of GLI2DN was confirmed by Western blot (see insert in Figure 3). Naïve CD4 + T cells do not constitutively express high levels of TGF-b1. We measured the level of TGF-b1 mRNA by RT-PCR before and after infection with the GLI constructs. As shown in Figure 3A, overexpression of the constitutively activated GLI2DN in naïve CD4 + T cells significantly increased TGF-b1 mRNA expression (n = 6, p = 0.0313) following stimulation with aCD3/aCD28-coated beads. Upregulation of GLI1 mRNA, a known GLI2-mediated gene, indicates that the GLI2DN protein is activating transcription in these lentivirally infected cells (data not shown). The infection efficiency was measured by infecting naïve CD4 + T cells with a control lentivirus expressing GFP (69% infection efficiency, Figure 3B). The phenotype of the naïve cells was CD4 + CD45RA + CD45RO - (Figures 3C & 3D). Although overexpression of transgenic GLI proteins can modulate TGF-b1 transcription in naïve CD4 + T cells, we wanted to assess the physiological role of GLI2 activation in primary cells that express high levels of TGF-b1. Previous studies have used siRNA to knockdown specific genes in primary Treg [31,32]. Knockdown of GLI2 was done using commercially available Dharmacon ACCELL siRNA to assess its function in TGF-b1 transcription in primary human Treg. GLI2 siRNA knockdown in primary human CD4 + CD25 hi Treg stimulated with aCD3/ aCD28 coated beads decreased the expression of TGF-b1 mRNA by approximately 5-fold ( Figure 4A, p = 0.0189). To assess the knockdown of GLI2 activity, GLI1 mRNA expression was measured by RT-PCR. GLI1 gene transcription is a known downstream target of the activated GLI2 transcription factor. The decreased expression of GLI1 mRNA supports the siRNAmediated knockdown of GLI2 ( Figure 4B, p = 0.0278). A separate independent negative control using a scrambled GLI2 siRNA sequence (5'-AAGGUAUGCGCUUAAUUU-3') was used to address off-target effects ( Figure 4C). These results indicate that GLI2 is important in regulating TGF-b1 transcription in primary human Treg. The sorted Treg were CD3 + CD8 -CD4 + CD25 hi -FoxP3 + T cells. The purity of the Treg was more than 85% ( Figure 4D).

GLI2 Binds to the Human TGF-b1 Promoter
Chromatin immunoprecipitation (ChIP) was done to assess the binding of GLI2 to the human TGF-b1 promoter. Primary human regulatory CD4 + CD25 hi T cells were negatively isolated and stimulated with aCD3/aCD28-coated beads overnight. The stimulated Treg were incubated with agarose beads coated with aGLI2 or aIgG control antibodies. As shown in Figure 5, GLI2 bound to the TGF-b1 promoter. GLI2 binding was shown to be at 'Site E' (Figure 5) in the human TGF-b1 promoter. However GLI2 did not bind to a non-targeting region in the human IL-10 promoter (Lane 8).

HIV-1 Tat Binds to GLI2
Increased plasma and cerebral spinal fluid (CSF) levels of immunosuppressive cytokines like TGF-b1 are found during HIV-1 disease progression [8][9][10] leading to an increase in iTreg [11,12]. The HIV-1 transactivator and viral protein Tat has been implicated as the inducer of TGF-b1 in both in vitro as well as in vivo models [13][14][15][16][17]. Although Tat has been shown to increase TGF-b1, the underlying transcriptional mechanism has not yet been clearly defined.
Since we found that GLI2 regulates TGF-b1 at the transcriptional level, we tested whether HIV-1 Tat binds to human GLI2 and can thereby increase or stabilize TGF-b1 transcription using co-immunopreciptation (co-IP) to assess the binding of human GLI2 to HIV-1 Tat. Dual transfections were done in 293T cells with three different sets of plasmids: (GLI2-6xMYC + HIV-1 Tat-FLAG), (GLI2-6xMYC + PCDNA3 control), (HIV-1 Tat-FLAG + PCDNA3 control). Forty-eight hours post-transfection, the cells were lysed and the released proteins were collected for co-IP (Pierce Co-IP Kit from Thermo Scientific). The agarose resin was coated with one of three antibodies: Sigma F1804 anti-FLAG M2 antibody (to bind Tat to bead), CST 71D10 anti-MYC antibody (to bind GLI2 to bead), or an isotype control antibody. Following co-IP, the elutions were run on an SDS-PAGE gel followed by Western Blotting. As shown in Figure 6, HIV-1 Tat bound specifically to GLI2 which was bound to a bead. The reverse reaction also showed specificity, indicating that these two proteins can indeed interact. The binding of HIV-1 Tat to GLI2 suggests a potential mechanism for TGF-b1 induction in HIV-1 infection. Further experiments will need to be done to test the functional synergy of HIV-1 Tat and GLI2 to affect transcription at the TGF-b1 promoter.

Discussion
Our results show that the transcription factor GLI2 plays a previously unknown, but important role in the complex transcriptional regulation of TGF-b1. Through in silico screening analysis we revealed six potential GLI-binding sites in the human TGF-b1 promoter, five of which were previously unknown. Using mutational analysis of the human TGF-b1 promoter, we found that GLI2 enhances TGF-b1 transcription in at least three of the five putative GLI-binding sites (Sites A, B, & E). In addition our results show that infection of primary naïve CD4 + T cells (low TGF-b1 expressing cells) with a constitutively active GLI2 lentivirus enhances TGF-b1 transcription. Furthermore, siRNA knockdown of GLI2 in primary human CD4 + CD25 hi FoxP3 + Treg (high TGF-b1 expressing cells) significantly decreased TGF-b1 transcription. We also show by ChIP that GLI2 directly binds to ''Site E'' in the TGF-b1 promoter. This newly identified mechanism GLI2-mediated TGF-b1 regulation may have implications in diseases such as cancer and AIDS, where high levels of TGF-b1 contribute to pathogenesis.
Although the role of GLI-mediated regulation of TGF-b1 transcription has not previously been shown, there is indirect evidence for this mechanism. Eichenmuller et al. discovered that Ptch1 knockout mice, which have constitutive activation of the SHH pathway, have more than 400-fold increased levels of TGF- Figure 5. GLI2 binds to the human TGF-b1 promoter. Chromatin immunoprecipitation (ChIP) was done to assess the binding of GLI2 to the human TGF-b1 promoter. Primary human regulatory CD4 + CD25 hi T cells were negatively isolated and stimulated with aCD3/aCD28-coated beads overnight. PCR was done to assess GLI2 binding. Whole DNA was used as a positive control for the PCR. GLI2 bound to the TGF-b1 promoter at 'Site E' in the human TGF-b1 promoter. GLI2 did not bind to a non-targeting region in the human IL-10 promoter (Lane 8). doi:10.1371/journal.pone.0040874.g005 b1 mRNA transcripts [28]. Although the investigators found that the putative GLI binding site in the second promoter was not responsive to GLI1, they did not investigate the role of GLI2 in regulating the five putative GLI binding sites that we discovered in the first TGF-b1 promoter.
Additionally, several reports emphasize the close relationship between the TGF-b1 and SHH/GLI families [33,34]. Liu et al. reported the interaction between the SHH pathway molecule GLI3 and the SMAD proteins (TGF-b1 pathway transcription factors) [35]. Additionally Dennler et al. reported that GLI2 and GLI1 could be induced through a SMAD-mediated mechanism [36]. The TGF-b superfamily genes BMP-2, 4, & 7 all have GLIresponsive elements in their promoters [37][38][39]. Lin et al. found a SHH-responsive element in the 59-upstream promoter region of TGF-b2 [40]. TGF-b1 and its effector molecule SMAD3 have been shown to upregulate GLI2 and GLI1 [36,41]. Despite the extensive cross-regulatory network of TGF-b and SHH, the regulation of TGF-b1 by SHH family members, such as the GLI proteins, has not been previously reported.
Several types of tumors (basal cell carcinomas, gliomas, medullablastomas, and prostate cancer) express abnormally high levels of GLI proteins or increased SHH pathway activation, which may be targets for therapy [42]. Although aberrant activation of SHH/GLI signaling leads to elevated expression of immunosuppressive factors like TGF-b1 [43][44][45][46][47][48][49], a clear mechanism of cancer-induced TGF-b1 induction is still lacking. One possible mechanism is through activation of GLI2 by the ERK and AKT pathways in tumor cells. The ERK and AKT pathways are hyperactivated in several tumors and are critical for GLIregulation in both tumor cells [50,51] as well as primary mammalian cells [52,53]. Our data indicate that the ERK and AKT pathways are also critical for GLI activation in CD4 + T cells (data not shown). The hyperactivation of the ERK and AKT pathways in tumor cells may provide an environment for GLI2mediated transcription of the immunosuppressive TGF-b1.
We also show that HIV-1 Tat binds to GLI2. The interaction between HIV-1 Tat and GLI2 may be a contributing factor to the elevated levels of TGF-b1 in HIV infection and contributes to immune dysregulation, a key characteristic of chronic HIV-1 disease. Increased plasma and cerebrospinal fluid (CSF) levels of immunosuppressive cytokines like TGF-b1 are found during HIV-1 disease progression [8][9][10] leading to an increase in iTreg [11,12]. This increase of immunoregulatory CD4 + CD25 + FoxP3 + T-cells (Treg) during chronic HIV infection disables the immune system's control over viral replication as well as opportunistic infections [12]. The HIV-1 transactivator Tat has been implicated as the inducer of TGF-b1 in both in vitro as well as in vivo models [13][14][15][16][17], although the underlying transcriptional mechanism has not been clearly defined.
Our current findings support those of Browning et al., who found that human GLI2 bound to HIV-1 Tat [54]. The role of the GLI proteins in retroviral replication have previously been reported by several groups [54][55][56][57]. Specifically, GLI-2 has been previously shown to interact with retroviral transactivators to increase viral transcription [54][55][56][57]. We suggest that the reported induction of TGF-b1 transcription by HIV-1 Tat [13][14][15][16][17] may be in part mediated by the binding of Tat to GLI2 at the TGF-b1 promoter. Although further studies will need to be done to validate this mechanism, the novel role of GLI2 in TGF-b1 transcription may provide an interesting link between HIV-1 replication and TGF-b1 induction.
The role of TGF-b1 in pathogenesis of cancer, AIDS, and several other diseases warrants interest in the regulation of this immunoregulatory cytokine. The regulatory role of GLI2 in TGF-b1 transcription extends our understanding of how the SHH and TGF pathways interact in mammalian biology. How GLI2 is regulated by the ERK and AKT pathways and by HIV-1 Tat may lead to insight into TGF-b1 induction during cancer progression and HIV infection. shown on right-hand side. Following washing and elution steps, the bound protein was run on a SDS-PAGE gel followed by Western Blotting to assess GLI2 binding. Anti-myc antibody was used to confirm binding of GLI2 to Tat when Tat was bound to the bead. (B) Beads were coated with anti-myc antibody and incubated with cell lysates from transfections #1-3 shown on right-hand side. Following washing and elution steps, the bound protein was run on a SDS-PAGE gel and Western Blotting was done to look for HIV-1 Tat binding. Bands developed at approximately 27 kDa. Anti-flag antibody was used to confirm binding of Tat to GLI2 when GLI2 was bound to the bead. doi:10.1371/journal.pone.0040874.g006